新药审批悦康药业YKYY013注射液9月22日,悦康药业宣布,其子公司悦康科创获得美国FDA同意,开展YKYY013注射液用于治疗慢性乙型肝炎病毒感染的临床试验。华东医药 HDM20179月22日,华东医药宣布,其子公司中美华东申报的注射用HDM2017药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验,适应症为晚期恶性实体瘤。科伦博泰 A4009月23日科伦博泰宣布,其转染过程中重排...
Source Link新药审批悦康药业YKYY013注射液9月22日,悦康药业宣布,其子公司悦康科创获得美国FDA同意,开展YKYY013注射液用于治疗慢性乙型肝炎病毒感染的临床试验。华东医药 HDM20179月22日,华东医药宣布,其子公司中美华东申报的注射用HDM2017药品临床试验申请已获得美国FDA批准,可在美国开展I期临床试验,适应症为晚期恶性实体瘤。科伦博泰 A4009月23日科伦博泰宣布,其转染过程中重排...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.